StocksMedium•25 September 2026•
1 min read
US FDA Approves AbbVie Parkinson's Disease Drug
Key Facts
1The US Food and Drug Administration approved AbbVie's drug for Parkinson's disease in adults.
The US Food and Drug Administration approved AbbVie's drug for Parkinson's disease in adults. Reuters reported that the approval follows the regulator's review of the drug's efficacy and safety, as updated on the FDA website.
ABBV closed at $265.12 on September 24, 2026, with the stock reaching a day high of $267.41 and a low of $263.09. This regulatory milestone is expected to impact the company's long-term revenue and position within the healthcare sector.